Cisatracurium 200 mg vials recalled after subpotent stability assay results
Somerset Therapeutics is recalling 28,660 vials of Cisatracurium Besylate Injection, 200mg/20mL, after out of specification assay results during long term stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 under the rule that FDA Class III actions fall at 1 or 2: the record cites a subpotent assay result with no stated clinical consequence.
Plain-English summary
Cisatracurium Besylate Injection USP, 200mg/20mL (10mg/mL), supplied as 10 x 20 mL single-dose vials per carton, manufactured for Somerset Therapeutics, LLC of Hollywood, Florida, made in India, under NDC 70069-151-01, is being recalled.
The reason given in the enforcement record is a subpotent product: out of specification assay results observed during long term stability testing.
The recall covers 28,660 20mL vials from lot A250020, expiry 06/30/2026. Distribution was nationwide in the USA. The FDA has classified the action as Class III, its least serious category.
The record describes a specification failure rather than a reported patient harm. Facilities should quarantine the affected lot and follow the firm's instructions.
The recalled product
- Product
- CISATRACURIUM BESYLATE (CISATRACURIUM BESYLATE)
- Brand
- CISATRACURIUM BESYLATE
- Manufacturer
- SOMERSET THERAPEUTICS LLC
- Category
- Drug — Neuromuscular blocker
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: A250020
- Exp Date 06/30/2026
UPCs (4)
- 0370069141014
- 0370069151013
- 0370069141106
- 0370069151105
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by SOMERSET THERAPEUTICS LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · CISATRACURIUM BESYLATE
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24
- ModerateCisatracurium 10 mg vials recalled after subpotent stability assay results
FDA (Drugs) · 2025-12-24
- CriticalCisatracurium Besylate Injection Recalled Due to Labeling Error
FDA (Drugs) · 2021-03-03
Same manufacturer · SOMERSET THERAPEUTICS LLC
See all →- HighDexamethasone injection failed impurity specifications at product expiry testing
FDA (Drugs) · 2026-03-25
- ModerateFDA Class III Atropine Sulfate Ophthalmic Solution Recall for Specification Failures
FDA (Drugs) · 2025-01-08
- HighHaloperidol Decanoate Injections Recalled for Trace Water Contamination
FDA (Drugs) · 2024-05-29
- LowSomerset Therapeutics Recalls Brimonidine Tartrate Ophthalmic Solution
FDA (Drugs) · 2020-07-15
- LowSomerset Therapeutics Recalls Brimonidine Tartrate Ophthalmic Solution Due to Label Leaching
FDA (Drugs) · 2020-07-15
Same hazard · subpotent
See all →- ModerateCAREone Earwax Removal Drops Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22
- HighCompounded vasopressin syringes recalled as subpotent by IntegraDose Compounding Services
FDA (Drugs) · 2026-06-24
- ModerateSkin Rehab calming hydrocortisone balm recalled as a subpotent drug
FDA (Drugs) · 2026-04-22
- Moderateglo Skin Beauty Remedy Gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22
- ModerateRhonda Allison calming skin gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22